The ITA provisionally suspends rider S’annara Grove for her apparent ADRV
The International Testing Agency (ITA), leading an independent anti-doping program for the Union Cycliste Internationale (UCI), confirms that it has provisionally suspended South African rider S’annara Grove following an adverse analytical finding (AAF) for ipamorelin.
The ITA reports that a sample collected during an out-of-competition testing mission conducted by the Commonwealth Sport on 28 July 2026 from S’annara Grove, a rider from South Africa, has returned an AAF1 for ipamorelin. The test was carried out in the scope of the 2026 Commonwealth Games, which took place in Glasgow, Scotland, from 23 July to 2 August 2026.
Ipamorelin is prohibited under the 2026 WADA Prohibited List as S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is prohibited at all times (in- and out-of-competition) and is a non-specified substance. Ipamorelin is a synthetic peptide used to stimulate the body’s natural production of growth hormone.
The rider has been informed of the case and, in accordance with the World Anti-Doping Code and Article 6.2.1 of the UCI Regulations for Results Management, a mandatory provisional suspension has been imposed on the rider. The rider has the right to challenge the provisional suspension and ask for its lifting.
Given that the case is underway, there will be no further comments made.
The original press release can be found here: https://ita.sport/news/the-ita-provisionally-suspends-rider-sannara-grove-for-her-apparent-adrv/
